Manchester Antenatal Vascular Service (MAViS)
Status
Conditions
Treatments
Details and patient eligibility
About
25-30% of women with preexisting vascular disease (chronic hypertension/diabetes/obesity) will develop pre-eclampsia and or growth restriction. In addition, the frequency of stillbirths in this group is dramatically increased over the general population. Pregnancy complications in this very heterogeneous group are likely to be a combination of a failure of the maternal vasculature to adapt to pregnancy and/or a failure of placental development. The relative contribution of these two mechanisms is poorly understood and current preventative strategies (aspirin) in this group only prevent a small number of adverse outcomes. This important and complex group have been inadequately investigated to date mainly because of the diversity of their underlying disease complicating prospective research studies.
The evolution of tools which allow more detailed assessments of both uteroplacental blood flow and maternal vascular function will enable us to perform prospective studies in these women and to develop targeted preventative measures. Recent biomarker studies have also identified a number of biomarkers which have not yet been assessed in these high risk groups.
Enrollment
Sex
Volunteers
Inclusion criteria
Women with preexisting vascular disease:
- chronic hypertension BP ≥140/90 at ≤14 weeks
- chronic hypertension requiring antihypertensive treatment ≤ 14 weeks
- pre gestational diabetes with evidence of vascular complications (hypertension, nephropathy)
- history of ischemic heart disease
- previous early onset pre-eclampsia (delivery < 32 weeks)
- Obesity (BMI ≥ 40) with any history of hypertension or booking BP≥130/80
Exclusion criteria
Women who do not meet the inclusion criteria
Trial design
750 participants in 1 patient group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal